Female Health Company (The) (NASDAQ: VERU) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
This table compares Female Health Company (The) and Amicus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Female Health Company (The)||-42.02%||-16.78%||-10.64%|
Valuation & Earnings
This table compares Female Health Company (The) and Amicus Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Female Health Company (The)||N/A||N/A||N/A||($0.19)||-9.89|
|Amicus Therapeutics||$16.28 million||137.37||-$186.93 million||($1.47)||-9.24|
Female Health Company (The) has higher revenue, but lower earnings than Amicus Therapeutics. Female Health Company (The) is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Female Health Company (The) has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Female Health Company (The) and Amicus Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Female Health Company (The)||0||0||2||0||3.00|
Female Health Company (The) presently has a consensus target price of $5.00, suggesting a potential upside of 165.96%. Amicus Therapeutics has a consensus target price of $18.07, suggesting a potential upside of 32.98%. Given Female Health Company (The)’s stronger consensus rating and higher possible upside, research analysts clearly believe Female Health Company (The) is more favorable than Amicus Therapeutics.
Institutional and Insider Ownership
5.0% of Female Health Company (The) shares are owned by institutional investors. 10.9% of Female Health Company (The) shares are owned by company insiders. Comparatively, 3.4% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Female Health Company (The) beats Amicus Therapeutics on 8 of the 11 factors compared between the two stocks.
Female Health Company (The) Company Profile
Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women’s Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.